Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

8 trials in Phase 3/4

Results Transparency

100%

8 of 8 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 3

8(100.0%)

8Total

Phase 3(8)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06042855Phase 3Completed

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Role: lead

NCT04885530Phase 3Completed

ACTIV-6: COVID-19 Study of Repurposed Medications

Role: lead

NCT05894577Phase 3Completed

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Role: lead

NCT05894564Phase 3Completed

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

Role: lead

NCT05894538Phase 3Completed

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)

Role: lead

NCT05890586Phase 3Completed

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

Role: lead

NCT05736874Phase 3Completed

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

Role: lead

NCT05736861Phase 3Completed

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

Role: lead

All 8 trials loaded